Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Puma BiotechnologyPBYI -3.03%53 EV-to-Revenue is 1.35 as of Aug. 04, 2026, which is 16% above its 10-year median of 1.16. GuruFocus rates PBYI with a GF Score™ of 53/100 and a GF Value™ of $3.34 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 955 Biotechnology companies, Puma Biotechnology ranks better than 86.07% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Puma Biotechnology's enterprise value is $305.8 Mil.
Puma Biotechnology's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $227.2 Mil. Therefore, Puma Biotechnology's EV-to-Revenue for today is 1.35.
The historical rank and industry rank for Puma Biotechnology's EV-to-Revenue or its related term are showing as below:
PBYI'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.45 Med: 1.16 Max: 781.34
Current: 1.35
During the past 13 years, the highest EV-to-Revenue of Puma Biotechnology was 781.34. The lowest was 0.45. And the median was 1.16.
PBYI's EV-to-Revenue is ranked better than 86.07% of 955
companies
in the Biotechnology industry
Industry Median: 8.08
vs PBYI: 1.35
Puma Biotechnology's share price for today is $7.69.
Puma Biotechnology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.46.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Puma Biotechnology EV-to-Revenue Related Terms
Puma Biotechnology EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for Puma Biotechnology's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBYI vs EVMN, OCGN, EDIT: EV-to-Revenue Comparison
For the Biotechnology subindustry, Puma Biotechnology's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Puma Biotechnology EV-to-Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Puma Biotechnology's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Puma Biotechnology's EV-to-Revenue falls into.
Puma Biotechnology's current Enterprise Value is $305.8 Mil.
Puma Biotechnology's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $227.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Puma Biotechnology (PBYI) has a EV-to-Revenue of 1.35 as of Aug. 04, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Puma Biotechnology and its competitors. This is 16% above median its historical median of 1.16. Over the past decade, Puma Biotechnology's EV-to-Revenue has ranged from 0.45 to 781.34. According to the industry distribution chart, Puma Biotechnology ranks #133 out of 955 companies in the Biotechnology industry, placing it in the top 13.9%.
Is Puma Biotechnology's EV-to-Revenue too high?
Puma Biotechnology's current EV-to-Revenue of 1.35 is 16% above median its 10-year median of 1.16. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 781.34. The Biotechnology industry median EV-to-Revenue is 8.08. Puma Biotechnology's value of 1.35 is 83.3% below this industry median. Based on the distribution chart, Puma Biotechnology ranks #133 out of 955 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Puma Biotechnology has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Puma Biotechnology's EV-to-Revenue compare to EVMN and OCGN?
According to the Biotechnology industry distribution chart, Puma Biotechnology ranks #133 out of 955 companies for EV-to-Revenue. This places Puma Biotechnology in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-Revenue is 8.08. Puma Biotechnology's value of 1.35 is 83.3% below this benchmark. Historically, Puma Biotechnology's own EV-to-Revenue has ranged from 0.45 to 781.34 over the past decade. While the company's 10-year median is 1.16 vs. the industry median of 8.08, Puma Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Biotechnology company?
The median EV-to-Revenue among Biotechnology companies is 8.08, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Puma Biotechnology's current EV-to-Revenue of 1.35 is 83.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Puma Biotechnology and its competitors. For the Biotechnology industry, the median EV-to-Revenue is 8.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Puma Biotechnology's current EV-to-Revenue is 1.35, which is 16% above median its own 10-year median of 1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Puma Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Puma Biotechnology (PBYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.34, compared to a current price of $7.69 — trading 130.2% above its estimated fair value. The current EV-to-Revenue is 1.35, which is 16% above median its 10-year median of 1.16 and 83.3% below the Biotechnology industry median of 8.08. Puma Biotechnology's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Puma Biotechnology (PBYI), the current EV-to-Revenue is 1.35 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Puma Biotechnology (PBYI) Overvalued in 2026?
Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued.
The current stock price of $7.69 is trading 130.2% above its estimated GF Value™ of $3.34.
GuruFocus considers Puma Biotechnology to be Significantly Overvalued.
Key valuation signals for PBYI:
EV-to-Revenue: 1.35 (16% above median its 10-year median of 1.16)
GF Value™: $3.34 vs. price of $7.69 (130.2% above fair value)
Industry Position: 83.3% below the Biotechnology median (#133 of 955)
No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score
Get the complete analysis for PBYI
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBYI has been successfully added to your 
